NCT03665701View on ClinicalTrials.gov

Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions
Atopic Asthma
Interventions
PROCEDURE

Blood Sampling

Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.

Trial Locations (1)

30625

Fraunhofer ITEM im CRC, Hanover

All Listed Sponsors
lead

Fraunhofer-Institute of Toxicology and Experimental Medicine

OTHER

NCT03665701 - Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites | Biotech Hunter | Biotech Hunter